
Sas

# Clinical Graphs Using SAS®



Sanjay Matange



# **Contents**

Abo	out This Book	ix
Abo	out The Author	. xiii
Acł	knowledgments	ΧV
Pre	face	xvii
Ch	apter 1: Introduction to ODS Graphics	1
1.1	A Brief History of ODS Graphics	1
1.2	Automatic Graphs from SAS Analytical Procedures	3
1.3	Create Custom Graphs Using the Graph Template Language (GTL)	4
1.4	Create Custom Graphs Using the Statistical Graphics (SG) Procedures	4
1.5	Create Custom Graphs Using the ODS Graphics Designer Application	5
1.6	Data Sets and ODS Styles	5
1.7	Color and Grayscale Graphs	6
1.8	Summary	6
Ch	apter 2: A Brief Overview of the SG Procedures	9
2.1	Single-Cell Graph Using the SGPLOT Procedure	10
2.2	Multi-Cell Classification Panels Using the SGPANEL Procedure	11
2.3	Multi-Cell Comparative Scatter Plots Using the SGCATTER Procedure	12
2.4	Automatic Features	12
2.5	The SGPLOT Procedure	13
	2.5.1 Required Roles	14
	2.5.2 Optional Data Roles	14
	2.5.3 Plot Options	14
2.6	Plot Layering	15
2.7	SGPANEL Procedure	16
	2.7.1 Layout PANEL	18
	2.7.2 Layout LATTICE	19
	2.7.3 Layout COLUMNLATTICE	20
	2.7.4 Layout ROWLATTICE	21

2.8	Combining Statements	22
2.9	Annotation	23
2.10	0 Styles and Their Usage	24
2.1 <sup>-</sup>	1 Summary	25
Ch	apter 3: Clinical Graphs Using the SAS 9.3 SGPLOT Procedure	27
3.1	Box Plot of QTc Change from Baseline	29
	3.1.1 Box Plot of QTc Change from Baseline with Outer Risk Table	29
	3.1.2 Box Plot of QTc Change from Baseline with Inner Risk Table	33
	3.1.3 Box Plot of QTc Change from Baseline in Grayscale	35
3.2	Mean Change in QTc by Week and Treatment	38
	3.2.1 Mean Change of QTc by Week and Treatment with Outer Table	38
	3.2.2 Mean Change of QTc by Week and Treatment with Inner Table	41
	3.2.3 Mean Change in QTc by Visit in Grayscale	43
3.3	Distribution of ASAT by Time and Treatment	45
3.4	Median of Lipid Profile by Visit and Treatment	47
	3.4.1 Median of Lipid Profile by Visit and Treatment on Discrete Axis	47
	3.4.2 Median of Lipid Profile by Visit and Treatment on Linear Axis in Grayscale	48
3.5	Survival Plot	50
	3.5.1 Survival Plot with External "Subjects At-Risk" Table	50
	3.5.2 Survival Plot with Internal "Subjects At-Risk" Table	52
	3.5.3 Survival Plot with Internal "Subjects At-Risk" Table in Grayscale	53
3.6	Simple Forest Plot	55
	3.6.1 Simple Forest Plot	55
	3.6.2 Simple Forest Plot with Study Weights	59
	3.6.3 Simple Forest Plot with Study Weights in Grayscale	60
3.7	Subgrouped Forest Plot	62
3.8	Adverse Event Timeline by Severity	64
3.9	Change in Tumor Size	67
3.10	0 Injection Site Reaction	70
3.1 <sup>-</sup>	1 Distribution of Maximum LFT by Treatment	72
	3.11.1 Distribution of Maximum LFT by Treatment with Multi-Column Data	72
	3.11.2 Distribution of Maximum LFT by Treatment Grayscale with Group Data	73
3.12	2 Clark Error Grid	75
	3.12.1 Clark Error Grid	75
	3.12.2 Clark Error Grid in Grayscale	76

3.13 The Swimmer Plot	77
3.13.1 The Swimmer Plot for Tumor Response over Time	77
3.13.2 The Swimmer Plot for Tumor Response in Grayscale	80
3.14 CDC Chart for Length and Weight Percentiles	82
3.15 Summary	86
Chapter 4: Clinical Graphs Using the SAS 9.4 SGPLOT Procedure	87
4.1 Box Plot of QTc Change from Baseline	89
4.1.1 Box Plot of QTc Change from Baseline	89
4.1.2 Box Plot of QTc Change from Baseline with Inner Risk Table and Bands	91
4.1.3 Box Plot of QTc Change from Baseline in Grayscale	93
4.2 Mean Change in QTc by Visit and Treatment	94
4.2.1 Mean Change in QTc by Visit and Treatment	94
4.2.2 Mean Change in QTc by Visit and Treatment with Inner Table of Subjects	96
4.2.3 Mean Change in QTc by Visit and Treatment in Grayscale	97
4.3 Distribution of ASAT by Time and Treatment	98
4.3.1 Distribution of ASAT by Time and Treatment	98
4.3.2 Distribution of ASAT by Time and Treatment in Grayscale	100
4.4 Median of Lipid Profile by Visit and Treatment	101
4.4.1 Median of Lipid Profile by Visit and Treatment on Discrete Axis	101
4.4.2 Median of Lipid Profile by Visit and Treatment on Linear Axis in Grayscale	102
4.5 Survival Plot	104
4.5.1 Survival Plot with External "Subjects At-Risk" Table	104
4.5.2 Survival Plot with Internal "Subjects At-Risk" Table	105
4.5.3 Survival Plot with Internal "Subjects At-Risk" Table in Grayscale	106
4.6 Simple Forest Plot	107
4.6.1 Simple Forest Plot	107
4.6.2 Simple Forest Plot with Study Weights	108
4.6.3 Simple Forest Plot with Study Weights in Grayscale	110
4.7 Subgrouped Forest Plot	111
4.8 Adverse Event Timeline by Severity	113
4.9 Change in Tumor Size	117
4.10 Injection Site Reaction	120
4.10.1 Injection Site Reaction	120
4.10.2 Injection Site Reaction in Gravscale	121

4.11 Distribution of Maximum LFT by Treatment	122
4.11.1 Distribution of Maximum LFT by Treatment with Multi-Column Da	ta122
4.11.2 Distribution of Maximum LFT by Treatment Grayscale with Group	Data 124
4.12 Clark Error Grid	125
4.12.1 Clark Error Grid	125
4.12.2 Clark Error Grid in Grayscale	126
4.13 The Swimmer Plot	128
4.13.1 The Swimmer Plot for Tumor Response over Time	128
4.13.2 The Swimmer Plot for Tumor Response over Time in Grayscale	130
4.14 CDC Chart for Length and Weight Percentiles	132
4.15 Summary	136
Chapter 5: Clinical Graphs Using the SGPANEL Procedure	137
5.1 Panel of LFT Shifts from Baseline to Maximum by Treatment	139
5.1.1 Panel of LFT Shifts with Common Clinical Concern Levels	139
5.1.2 Panel of LFT Shifts with Individual Clinical Concern Levels	140
5.2 Immunology Profile by Treatment	142
5.2.1 Immunology Panel	142
5.2.2 Immunology Panel in Grayscale	143
5.3 LFT Safety Panel, Baseline vs Study	144
5.3.1 LFT Safety Panel, Baseline vs Study	144
5.3.2 LFT Safety Panel, Baseline vs Study	145
5.4 Lab Test Panel	146
5.4.1 Lab Test Panel with Clinical Concern Limits	146
5.4.2 Lab Test Panel with Box Plot, Band, and Inset Line Name	147
5.5 Lab Test for Patient over Time	148
5.5.1 Lab Test Values by Subject over Study Days	148
5.5.2 Lab Test Values by Subject with Study Days Band	149
5.6 Vital Statistics for Patient over Time	150
5.6.1 Vital Statistics for Patient over Time	150
5.6.2 Vital Statistics for Patient over Time	151
5.7 Eye Irritation over Time by Severity and Treatment	153
5.7.1 Eye Irritation over Time by Severity and Treatment	153
5.7.2 Vital Statistics for Patient over Time in Grayscale	154
5.8 Summary	155

Ch	apter 6: A Brief Review of the Graph Template Language	157
6.1	Getting Started	. 158
6.2	A Simple GTL Graph	. 159
6.3	GTL Graphs and Terminology	. 161
6.4	GTL Plot Statements	. 163
	6.4.1 Basic Plots	. 163
	6.4.2 Categorical Plots	. 164
	6.4.3 Distribution Plots	. 164
	6.4.4 Fit Plots	. 164
	6.4.5 Parametric Plots	. 164
	6.4.6 3-D Plots	. 165
	6.4.7 Other Plots	. 165
6.5	GTL Layout Statements	. 165
	6.5.1 The Graph Container	. 165
	6.5.2 Single-Cell Layouts	. 165
	6.5.3 Multi-cell Ad Hoc Layouts	. 166
	6.5.4 Multi-Cell Classification Panels	. 166
6.6	GTL Title, Footnote, and Entry Statements	. 167
6.7	GTL Legend Statements	. 167
6.8	GTL Attribute Maps	. 167
6.9	GTL Dynamic Variables and Macro Variables	. 167
6.10	0 GTL Expressions and Conditionals	. 168
6.1	1 GTL Draw Statements	. 168
6.12	2 GTL Annotate	. 168
6.13	3 Summary	. 169
Ch	apter 7: Clinical Graphs Using SAS 9.3 GTL	171
7.1	Distribution of ASAT by Time and Treatment	. 173
7.2	Most Frequent On-Therapy Adverse Events Sorted by Relative Risk	. 176
7.3	Treatment Emergent Adverse Events with Largest Risk Difference with NNT	. 179
7.4	Butterfly Plot of Cancer Deaths by Cause and Gender	. 182
7.5	Forest Plot of Impact of Treatment on Mortality by Study	. 186
7.6	Forest Plot of Hazard Ratios by Patient Subgroups	. 191
7.7	Product-Limit Survival Estimates	. 197
7.8	Bivariate Distribution Plot	. 203
7.9	Summary	. 208

Chapter 8: Clinical Graphs Using SAS 9.4 GTL	209
8.1 Distribution of ASAT by Time and Treatment	211
8.2 Most Frequent On-Therapy Adverse Events Sorted by Relative Risk	213
8.3 Treatment Emergent Adverse Events with Largest Risk Difference with NNT	216
8.4 Butterfly Plot of Cancer Deaths by Cause and Gender	218
8.5 Forest Plot of Impact of Treatment on Mortality by Study	222
8.6 Forest Plot of Hazard Ratios by Patient Subgroups	226
8.7 Product-Limit Survival Estimates	231
8.8 Bivariate Distribution Plot	236
8.9 Summary	240
Index	243

From <u>Clinical Graphs Using SAS®</u>, by Sanjay Matange. Copyright © 2016, SAS Institute Inc., Cary, North Carolina, USA. ALL RIGHTS RESERVED.

Note: This short excerpt was taken from a chapter in the published book.

# 4.3 Distribution of ASAT by Time and Treatment

The graphs below consist of three sections. The main body of the graph contains the display of ASAT by Week and Treatment in the middle. A table of subjects in the study by treatment is at the bottom, and the number of subjects with value > 2 by treatment is at the top of the graph.

# 4.3.1 Distribution of ASAT by Time and Treatment

The values of ASAT by week and treatment are displayed using a box plot. The x-axis type is linear.




Figure 4.3.1 - Distribution of ASAT by Time and Treatment

This graph is likely one of the most complex displays that can be created using the SGPLOT procedure. This graph displays the distribution of ASAT by treatment over time using a grouped

box plot on a linear x-axis. The visit values are scaled correctly on the time axis. The smallest interval between the visits determines the "effective" midpoint spacing used for adjacent placement of the treatment values.

```
title 'Distribution of ASAT by Time and Treatment';
proc sgplot data=asat;
 vbox asat / category=week group=drug name='box' nofill;
  xaxistable gt2 / class=drugGT colorgroup=drugGT position=top
         location=inside separator valueattrs=(size=6)
         labelattrs=(size=7);
  xaxistable count / class=drug colorgroup=drug position=bottom
         location=inside separator valueattrs=(size=6)
         labelattrs=(size=7);
  refline 1 / lineattrs=(pattern=shortdash);
  refline 2 / lineattrs=(pattern=dash);
  refline 25 / axis=x;
 xaxis type=linear values=(0 2 4 8 12 24 28) offsetmax=0.05
       valueattrs=(size=7) labelattrs=(size=8);
  vaxis offsetmax=0.1 valueattrs=(size=7) labelattrs=(size=8);
  keylegend 'box' / location=inside position=top linelength=20;
```

An XAXISTABLE statement is used to display the "Number of Subjects" values at the bottom of the graph. A second XAXISTABLE at the top is used to display the count of values above 2.0 by treatment.

# 4.3.2 Distribution of ASAT by Time and Treatment in Grayscale

The graph in Figure 4.3.2 is the same as above in grayscale. Markers are used in the legend for treatment.




Figure 4.3.2 - Distribution of ASAT by Time and Treatment in Grayscale

Drawing this graph using the Journal style poses a few challenges, mainly in the drawing of the boxes and their representation in the legend. Using the Journal style, the boxes for Drug "B" will get drawn using dashed lines. Because those look odd, I set the STYLEATTRS option to use only solid lines.

```
ods listing style=journal;
title 'Distribution of ASAT by Time and Treatment';
proc sqplot data=asat2;
 styleattrs datalinepatterns=(solid);
 vbox asat / category=week group=drug nofill;
 scatter x=week y=asat2 / group=drug name='s';
 xaxistable qt2 / class=druqGT colorqroup=druqGT position=top
       location=inside;
 xaxistable count / class=drug colorgroup=drug position=bottom
       location=inside;
 refline 1 / lineattrs=(pattern=shortdash);
 refline 2 / lineattrs=(pattern=dash);
 refline 25 / axis=x;
 xaxis type=linear values=(0 2 4 8 12 24 28) offsetmax=0.05;
 vaxis offsetmax=0.1 valueattrs=(size=8) labelattrs=(size=9);
 keylegend 's' / location=inside position=top linelength=20;
run;
```

Although this improves the rendering of the boxes, it will put two solid lines in the legend for "A" and "B". It would be better to show the mean markers in the legend instead. To do this, I have to add a scatter plot of asat2 by Week and Drug and include that in the legend. Because values in "asat2" are all missing, no markers are displayed in the graph itself, but the group markers are displayed in the legend. Relevant details are shown in the code snippet above. For full details, see Program 4\_3.

# 4.4 Median of Lipid Profile by Visit and Treatment

This graph displays the median of the lipid values by visit and treatment. The visits are at regular intervals and represented as discrete data.

# 4.4.1 Median of Lipid Profile by Visit and Treatment on Discrete Axis

The values for each treatment are displayed along with the 95% confidence limits as adjacent groups using GROUPDISPLAY option of "Cluster" and the option CLUSTERWIDTH=0.5. The HTMLBlue style is used.




Figure 4.4.1 - Median of Lipid Profile by Visit and Treatment

```
markerfillattrs=(color=white);
  keylegend 's' / title='Treatment' linelength=20;
  yaxis label='Median with 95% CL' grid;
  xaxis display=(nolabel);
run;
```

This graph displays the median of the lipid data by visit and treatment. The visits are at regular intervals and represented as discrete data. However, they could also be on a time axis with unequal intervals. The values for each treatment are displayed along with the 95% confidence limits as adjacent groups using GROUPDISPLAY=Cluster and CLUSTERWIDTH=0.5.

The values across visits are joined using a series plot. Note, the series plot also uses cluster groups with the same cluster width. The lengths of the line segments in the legends are reduced using the LINELENGTH option. Markers with fill and outlines are used with specific fill attributes.

Relevant details are shown in the code snippet above. For full details, see Program 4.4.

# 4.4.2 Median of Lipid Profile by Visit and Treatment on Linear Axis in Grayscale

This graph displays the median of the lipid data by treatment in grayscale on a linear x-axis.




Figure 4.4.2 – Median of Lipid Profile by Visit and Treatment on Linear Axis

title 'Median of Lipid Profile by Visit and Treatment'; proc sgplot data=lipid Liner grp; styleattrs datasymbols=(circlefilled trianglefilled squarefilled diamondfilled); series x=n y=median / group=trt groupdisplay=cluster

```
clusterwidth=0.5;
scatter x=n y=median / yerrorlower=lcl yerrorupper=ucl group=trt
    groupdisplay=cluster clusterwidth=0.5
    errorbarattrs=(thickness=1) filledoutlinedmarkers
    markerattrs=(size=7) name='s'
    markerfillattrs=(color=white);
keylegend 's' / title='Treatment' linelength=20;
yaxis label='Median with 95% CL' grid;
xaxis display=(nolabel) values=(1 4 8 12 16);
run;
```

The visits are not at regular intervals and are displayed at the correct scaled location along the x-axis. The visits are at week 1, 2, 4, 8, 12, and 16. These values are formatted to the strings shown on the axis. "Visit 1" collides with "Baseline", causing alternate tick values to be dropped, so I removed "1" from the tick value list.

As you can see, the group values are displayed as clusters, and the "effective midpoint spacing" is the shortest distance between the values. The markers are reduced in size to show the clustering. This can be adjusted by setting marker SIZE=7. Four filled markers are assigned to the list of markers.

Relevant details are shown in the code snippet above. For full details, see Program 4\_4.

#### 4.5 Survival Plot

The survival plot is one of the most popular graphs that users want to customize to their own needs. Here I have run the LIFETEST procedure to generate the data for this graph. The output is saved into the "SurvivalPlotData" data set. For more information about the LIFETEST procedure, see the SAS/STAT documentation.

# 4.5.1 Survival Plot with External "Subjects At-Risk" Table

The survival plot shown below in Figure 4.5.1 has the traditional arrangement where the table of Subjects At-Risk is displayed at the bottom of the graph, below the x-axis.




Figure 4.5.1 - Survival Plot with External "Subjects At-Risk" Table

```
ods output Survivalplot=SurvivalPlotData;
proc lifetest data=sashelp.BMT plots=survival(atrisk=0 to 2500 by 500);
   time T * Status(0);
   strata Group / test=logrank adjust=sidak;
   run:
```

A step plot of survival by time by strata displays the curves. A scatter overlay is used to draw the censored values, and an XAXISTABLE statement is used to display the at-risk values at the bottom of the graph. Relevant details are shown in the code snippet above. For full details, see Program 4 5.

```
title 'Product-Limit Survival Estimates';
title2 h=0.8 'With Number of AML Subjects at Risk';
proc sgplot data=SurvivalPlotData;
  step x=time y=survival / group=stratum
```

# 4.5.2 Survival Plot with Internal "Subjects At-Risk" Table

The graph shown here is mostly similar to the graph in Section 4.5.1, with the difference that the "Subjects At-Risk" table is moved above the x-axis, close to the rest of the data. Bringing all the data closer makes it easy to align the values with the data, and that improves the effectiveness of the graph.




Figure 4.5.2 - Survival Plot with Internal "Subjects At-Risk" Table

1: ALL -

```
title 'Product-Limit Survival Estimates';
title2 h=0.8 'With Number of AML Subjects at Risk';
proc sgplot data=SurvivalPlotData;
step x=time y=survival / group=stratum lineattrs=(pattern=solid)
    name='s';
scatter x=time y=censored / markerattrs=(symbol=plus) name='c';
scatter x=time y=censored / markerattrs=(symbol=plus) GROUP=stratum;
xaxistable atrisk / x=tatrisk location=inside class=stratum
    colorgroup=stratum separator valueattrs=(size=7 weight=bold)
labelattrs=(size=8);
```

- 2: AML-High Risk -

- 3: AML-Low Risk

```
keylegend 'c' / location=inside position=topright;
keylegend 's';
run;
```

All this graph needs is to simply specify LOCATION=Inside for the XAXISTABLE statement. In addition to that, we have switched on the separator that draws the horizontal line between the table and the curves.

Relevant details are shown in the code snippet above. For full details, see Program 4 5.

# 4.5.3 Survival Plot with Internal "Subjects At-Risk" Table in Grayscale

Displaying the survival plot in a grayscale medium presents some challenges.

Here we cannot use colors to identify the strata. Normally, the Journal style uses line patterns to identify the groups. Although line patterns work well for curves, they are not so effective with step plots because of the frequent breaks. So, it is preferable to use solid lines for all the levels of the step plot and to use markers to identify the strata.




Figure 4.5.3 - Survival Plot with Internal "Subjects At-Risk" Table in Grayscale

```
title 'Product-Limit Survival Estimates';
title2 h=0.8 'With Number of AML Subjects at Risk';
proc sgplot data=SurvivalPlotData;
  step x=time y=survival / group=stratum lineattrs=(pattern=solid)
      name='s' curvelabel curvelabelattrs=(size=6) splitchar='-';
  scatter x=time y=censored / name='c'
      markerattrs=(symbol=circlefilled size=4);
  xaxistable atrisk / x=tatrisk location=inside class=stratum
```

```
colorgroup=stratum separator valueattrs=(size=7 weight=bold)
labelattrs=(size=8);
keylegend 'c' / location=inside position=topright;
run;
```

In this case, markers are also used to identify the censored observations. So, I have chosen to use the CURVELABEL option with the SPLITCHAR option to identify the curves. This results in a clean and effective graph, without the need for a legend for the strata.

Relevant details are shown in the code snippet above. For full details, see Program 4 5.

Note: This short excerpt was taken from a chapter in the published book.

From *Clinical Graphs Using SAS®*, by Sanjay Matange. Copyright © 2016, SAS Institute Inc., Cary, North Carolina, USA. ALL RIGHTS RESERVED.

# Index

A	butterfly plot, of cancer deaths by cause and gender 182-
Adverse Event Timeline, by severity 64–67, 113–	186, 218–222
116	С
analytical procedures, automatic graphs from 3	categorical plots 164
annotations 23–24, 161, 168	categorization plots 22
ARROW function 24	cause, butterfly plot of cancer deaths by 182–186, 218–
ASAT, distribution of by time and treatment 45-	222
47, 173–176	CDC short for langth and weight persontiles 92, 96, 122
attribute maps	CDC chart, for length and weight percentiles 82–86, 132–136
about 25	cell 11, 162
GTL 160, 167	
ATTRPRIORITY 151	Clark Error Grid 75–77, 125–127
automatic graphs, from analytical procedures 3	COLAXIS statement 140, 146, 148
axes	COLN() function 223
defined 11, 163	color graphs 6
in GTL 160	COLORMODEL action 167
AXIS statement 15	COLORMODEL option 167 COLUMNLATTICE layout 20, 153, 154, 155
AXISEXTENT option 113	· · · · · · · · · · · · · · · · · · ·
AXISEXTENT=DATA option 109, 122	COLUMNWEIGHTS option 228 combining statements 22
AXISTABLE statement 210, 211, 212, 224, 227,	COMPARE statement 10
228, 233	
В	conditional statements (GTL) 160 conditionals (GTL) 168
D	confidence plots 22
BAND statement 93	container, graph 165
bands	Cravets, Matt 179, 216
box plot of QTc change from baseline with	CURVELABEL option 107
91–92	custom graphs
lab test panel with 147–148	creating using Graph Template Language (GTL) 4
BARCHART statement 210	creating using ODS Graphics Designer application 5
baseline	creating using ODS Graphics Designer application 5 creating using Statistical Graphics (SG) procedures 4
box plot of QTc change from 29–37, 89–94	creating using Statistical Graphics (5G) procedures 4
panel of LFT shifts from to maximum by	D
treatment 139–141	data sets, ODS styles and 5
basic plots 22, 163	DATALABEL option 187
bivariate distribution plot 203–207, 236–240	DATALATTICE layout 166
BLOCK statement 142	DATAPANEL layout 166
BLOCKPLOT statement 199	DATATRANSPARENCY option 223
box plot	discrete axis, median of lipid profile by visit and treatment
lab test panel with 147–148	on 47–48, 101–102
of QTc change from baseline 29–37, 89–94	DISCRETEATTRMAP statement 167, 229
BOXPLOT statement 210	DISCRETEATTRVAR statement 229

DISCRETELEGEND statement 178, 215	annotate 168
distribution	attribute maps 167
of ASAT by time and treatment 45-47, 98-	conditionals 168
101, 173–176, 211–212	creating custom graphs using 4
of maximum LFT by treatment 72-74, 122-	draw statements 168
125	dynamic variables 167–168
distribution plots 22, 164	entry statements 167
draw statements 168	expressions 168
DRAWARROW statement 168	footnote statements 167
DRAWLINE statement 168	getting started 158–159
DRAWRECTANGLE statement 168	graphs and terminology 161–163
DRAWTEXT statement 168, 188, 189, 194, 199,	layout statements 165–166
224, 225, 229, 233	legend statements 167
DROPLINE statement 123	macro variables 167–168
DYNAMIC statement 168	plot statements 163–165
dynamic variables (GTL) 160, 167–168	simple graph 159–161
	title statements 167
E	graphs
END statement 177, 214	defined 11, 162
ENDGRAPH statement 177, 214	GTL 161–163
ENDLAYOUT statement 177, 214	simple GTL 159–161
entries (GTL) 160	grayscale
ENTRY statement 168, 188-189, 192, 204, 224,	about 6
228, 238	box plot of QTc change from baseline in 35–37, 93-
entry statements (GTL) 167	94
ENTRYTITLE statement 159	Clark Error Grid in 76–77, 126–127
expressions (GTL) 160, 168	distribution of ASAT by time and treatment in 100–
external "Subjects At-Risk" table, survival plot	101
with 50-52, 104-105	distribution of maximum LFT treatment in 124–125
eye irritation, over time by severity and treatment	immunology panel in 143–144
153–154	injection site reaction in 121–122
F	mean change in QTc by visit and treatment in 97–98
	mean change in QTc by visit in 43–44
fit plots 22, 164	
footnotes (GTL) 160, 167	median of lipid profile by visit and treatment in linea
forest plots	axis in 102–103
of hazard ratios by patient subgroups 191–197, 226–231	median of lipid profile by visit and treatment on linear axis in 48–49
of impact of treatment on mortality by study	simple forest plot with study weights in 60-61, 110-
186–190, 222–226	survival plot with internal "Subjects At-risk" table in
functions	*
See specific functions	53–54, 106–107
G	swimmer plot for tumor response in 80–81 swimmer plot for tumor response over time in 130–
gender, butterfly plot of cancer deaths by 182–	
	131
186, 218–222 Graph Template Language (GTL)	vital statistics for patient over time in 154
See also 9.3 GTL	GRIDDED layout 166
See also 9.4 GTL	group data, distribution of maximum LFT treatment in
about 1, 157–158	grayscale with 124–125
aoout 1, 13/-130	GROUPDISPLAY option 101–102

GROUPDISPLAY=CLUSTER option 90, 95	layouts
GTL (Graph Template Language)	in GTL 160
See Graph Template Language (GTL)	multi-cell ad hoc 166
Н	single-cell 165–166
hazard ratios, forest plot of by patient subgroups	legend statements (GTL) 167
191–197, 226–231	legends defined 11, 163
HIGHCAP option 66, 115	GTL 160
HIGHFLOW statement 42	length percentiles, CDC chart for 82–86, 132–136
HIGHLABEL option 193	LFT safety panel, baseline <i>versus</i> study 144–145
HIGHLOW plot statement 62	LFT shifts, panel of from baseline to maximum by
HIGHLOWPLOT statement 193, 194	treatment 139–141
history, of ODS Graphics 1–2	LIFETEST procedure 3, 50-51, 198, 231-232
l	LINE function 24, 31
IMAGE function 24	linear axis
immunology profile, by treatment 142–144	median of lipid profile by visit and treatment in 102
INDENT option 112	103
injection site reaction 70–71, 120–122	median of lipid profile by visit and treatment on 48-
in-line draw, in GTL 161	49
inner risk table, box plot of QTc change from	LINELENGTH option 90, 102, 151
baseline with 33–35, 91–92	lipid profile, median of by visit and treatment 47–49
inner table	LOCATION=INSIDE option 93, 97, 106
mean change in QTc by visit and treatment	LOCATION=OUTSIDE option 90, 95
with 96–97	LOWLABEL option 43, 66, 115, 193
mean change of QTc by week and treatment	M
with 41–43	macro variables (GTL) 160, 167-168
INNERMARGIN statement 227, 228	MARKERCHAR statement 42, 57, 62, 77, 172
inset line name, lab test panel with 147–148	MARKERCHARACTER option 174, 175, 180, 184,
INSET statement 15, 86, 136, 148, 152	187–188, 189, 194
insets 11	MATRIX statement 10
INTERMARGIN statement 212	maximum LFT by treatment, distribution of 72-74
internal "Subjects At-risk" table, survival plot with 52–53, 53–54, 105–106, 106–107	mean change
1TEMSIZE option 220	in QTc by visit and treatment 94–98
	in QTc by week and treatment 38–44
K	median, of lipid profile by visit and treatment 47–49,
KEYLEGEND statement 15, 90, 95	101–103
Kopicko, Jeff 179, 216	%MODSTYLE() macro 25, 43, 49, 56, 68, 70, 77
L	multi-cell ad hoc layouts 166
LATTICE layout 19, 150, 151, 155, 166	multi-cell classification panels 11–12, 166 multi-cell comparative scatter plots 12
layering plots 15–16	multi-column data, distribution of maximum LFT by
LAYOUT LATTICE statement 172, 173–174,	treatment with 122–123
177, 183, 187, 192, 198, 204, 210,	
214	N
LAYOUT OVERLAY statement 172, 173–174,	N() function 168
177, 201, 210, 212, 214	9.3 GTL
layout statements	See also Graph Template Language (GTL)
defined 163	See also SGPLOT procedure
GTL 165–166	about 171–172

	bivariate distribution plot 203–207	most frequent on-therapy adverse events sorted by
	butterfly plot of cancer deaths by cause and	relative risk 213–215
	gender 182–186	product-limit survival estimates 231-236
	distribution of ASAT by time and treatment	treatment emergent adverse events with largest risk
	173–176	difference with NNT 216–218
	forest plot of hazard ratios by patient	9.4 SGPLOT procedure
	subgroups 191–197	See also SGPLOT procedure
	forest plot of impact of treatment on	about 88
	mortality by study 186–190	Adverse Event Timeline by severity 113–116
	most frequent on-therapy adverse events	box plot of QTc change from baseline 89–94
	sorted by relative risk 176–178	CDC chart for length and weight percentiles 132–
	product-limit survival estimates 197–202	136
	treatment emergent adverse events with	change in tumor size 117–119
	largest risk difference with NNT 179–	Clark Error Grid 125–127
	182	distribution of ASAT by time and treatment 98–101
0.2	SGPLOT procedure	
9.3	about 28	distribution of maximum LFT by treatment 122–125
		injection site reaction 120–122
	adverse event timeline by severity 64–67	mean change in QTc by visit and treatment 94–98
	box plot of QTc change from baseline 29–37	median of lipid profile by visit and treatment 101–
	CDC chart for length and weight percentiles	103
	82–86	simple forest plot 107–111
	change in tumor size 67–69	subgrouped forest plot 111–113
	Clark Error Grid 75–77	survival plot 104–107
	distribution of ASAT by time and treatment	swimmer plot 128–131
	45–47	NNT
	distribution of maximum LFT by treatment	treatment emergent adverse events with largest risk
	72–74	difference with 179–182, 216–218
	injection site reaction 70–71	NOHEADER option, PANELBY statement 148, 152
	mean change in QTc by week and treatment	0
	38–44	
	median of lipid profile by visit and treatment	ODS Graphics
	47–49	about 1
	simple forest plot 55–61	history of 1–2
	subgrouped forest plot 62-64	ODS Graphics Designer application
	survival plot 50–54	about 1
	swimmer plot 77–81	creating custom graphs using 5
9.4	GTL	ODS LISTING statement 36
	See also Graph Template Language (GTL)	ODS OUTPUT statement 198, 232
	about 209–210	ODS styles, data sets and 5
	bivariate distribution plot 236–240	OFFSETMAX option 189, 225
	butterfly plot of cancer deaths by cause and	options
	gender 218–222	See specific options
	distribution of ASAT by time and treatment	outer risk table, box plot of QTc change from baseline
	211–212	with 29–32
	forest plot of hazard ratios by patient	outer table, mean change of QTc by week and treatment
	subgroups 226–231	with 38–40
	forest plot of impact of treatment on	OVAL function 24, 31
	mortality by study 222–226	OVERLAY layout 165
	mortanty by study 222–220	OVERLAYED layout 166

OVERLAYEQUATED layout 165	ROWWEIGHTS option 232
P	RUN statement 177, 214
PAD option 30, 39	S
PANEL layout 18, 155	SCATTER statement 39, 41, 43, 48, 56, 57, 58, 62, 95,
PANELBY statement, NOHEADER option 148,	172, 187, 195, 210, 215
152	SCATTERPLOT statement 108, 174, 178, 180, 184, 188
parametric plots 164	189, 194, 210, 223
PATTERN option 223	SEPARATOR option 97
plot attributes, in GTL 161	SERIES statement 38, 95
PLOT statement 10	severity
plot statements	adverse event timeline by 64–67
defined 11, 162	Adverse Event Timeline by 113–116
GTL 163–165	eye irritation over time by 153–154
plots	SG
basic 163	See Statistical Graphics (SG) procedures
categorical 164	SGANNO option 23, 30, 39, 46, 51
categorization 22	SGPANEL procedure
confidence 22	about 4, 10, 137–138
distribution 22, 164	COLUMNLATTICE layout 20
fit 22, 164	eye irritation over time by severity and treatment
forest 186–190, 191–197, 222–226, 226–231	153–154
in GTL 160	immunology profile by treatment 142–144
layering 15–16	lab test for patient over time 148–150
parametric 164	lab test panel 146–148
3-D 165	LATTICE layout 19
POLYGON function 24, 88	LFT safety panel, baseline <i>versus</i> study 144–145
POLYLINE function 24	multi-cell classification panels using 11–12
product-limit survival estimates 197–202, 231–	PANEL layout 18
236	panel of LFT shifts from baseline to maximum by
PROTOTYPE layout 166	treatment 139–141
Q	ROWLATTICE layout 21
QTc	syntax for 16–17
box plot of change from baseline 29–37	vital statistics for patient over time 150–152
mean change in by week and treatment 38–	SGPLOT procedure
44	See also 9.3 SGPLOT procedure
R	See also 9.4 SGPLOT procedure
	about 4, 10
RANGEATTRMAP statement 167	optional data roles for 14
RECTANGLE function 24	plot options for 14 required roles for 14
REFERENCELINE statement 188, 193, 194, 223	single-cell graph using 10–11
REFLINE statement 34, 58, 73, 113, 140, 141,	syntax for 13
148	SGRENDER procedure 1, 158, 160, 167–168, 205, 239
REGION layout 166	SGSCATTER procedure
relative risk, most frequent on-therapy adverse	about 4, 10
events sorted by 176–178, 213–215	multi-cell comparative scatter plots using 12
ROWAXIS statement 140	SIDEBAR statement 227
ROWHEIGHTS option 198	simple forest plot 55–61, 107–111
ROWLATTICE ;layout 21, 155	5p. 101000 plot 55 01, 107 111

single-cell graph, using SGPLOT procedure 10-	vital statistics for patient over 150-152
11	titles (GTL) 160, 167
single-cell layouts 165–166	treatment
SPLITCHAR option 107	distribution of ASAT by 45-47, 98-101, 173-176,
statements, combining 22	211–212
See also specific statements	distribution of maximum LFT by 72–74, 122–125
StatGraph templates 4, 158, 165, 172	eye irritation over time by 153–154
Statistical Graphics (SG) procedures	forest plot of impact of on mortality by study 186-
about 1, 9–10	190
annotation 23–24	immunology profile by 142–144
automatic features 12–13	mean change in QTc by 38-44, 94-98
combining statements 22	mean of lipid profile by 47–49
creating custom graphs using 4	median of lipid profile by 101–103
plot layering 15–16	panel of LFT shifts from baseline to maximum by
SGPANEL 16–21	139–141
SGPLOT 13–14	tumor size, change in 67–69, 117–119
styles 24–25	U
study days, lab test values by subject with 148–149, 149–150	UNISCALE option 155
study weights, simple forest plot with 59-61,	V
108–109, 110–111	VALUES option 90
STYLEATTRS statement 15, 25, 94, 98, 100,	VALUESDISPLAY option 142
109, 113, 118, 121, 122, 126, 143–	VBAR statement 69, 70, 119, 120
144, 153	VBARPARM statement 69, 119
styles	VBOX statement 34, 45, 72–73, 90, 123
GTL 161	visit
SG (Statistical Graphics) procedures 24–25	mean change in QTc by 94–98
subgrouped forest plot 62–64, 111–113	mean of lipid profile by 47–49
survival plot 50-54, 104-107	median of lipid profile by 101–103
swimmer plot 77–81, 128–131	
SYMBOLCHAR statement 15	
SYMBOLIMAGE statement 15	W
Т	week, mean change in QTc by 38-44
TEMPLATE procedure 1, 4, 25, 157, 160, 172, 177, 210, 214	weight percentiles, CDC chart for 82–86, 132–136
terminology (GTL) 161–163	X
TEXT statement 24, 31, 88, 108	XAXIS statement 34, 45, 90
3-D plots 165	XAXISTABLE statement 88, 89, 90, 93, 95, 97, 99, 104
TICKVALUEALIGN option 224	106
TICKVALUEPRIORITY option 228	XERRORLOWER option 228
time	XERRORUPPER option 228
distribution of ASAT by 45–47, 98–101,	Υ .
173–176, 211–212	-
eye irritation over by severity and treatment	Y2AXIS statement 42, 43, 85, 135
153–154	YAXIS statement 34, 42, 85, 135, 136
lab test for patient over 148–150	YAXISOPTS 175, 189, 212, 225
swimmer plot for tumor response over 77– 79, 128–130, 130–131	YAXISTABLE statement 88, 108, 109, 112, 130

# **About This Book**

# **Purpose**

SAS users in the Health and Life Sciences industry need to create complex graphs so that biostatisticians and clinicians can use them for analysis of the data. The graphs are also used for submissions to FDA for drug approvals. These graphs have specific requirements and must be designed to deliver the data accurately and clearly without distractions. Many users do not have the skills with SAS graphics tools such as Statistical Graphics (SG) procedures and the Graph Template Language (GTL) to create such graphs. This book provides the know-how and the code to create the graphs that are commonly used in this industry.

#### Is This Book for You?

This book is for the SAS graphics programmer who is responsible for creating sophisticated graphs for the analysis of clinical trials data. Most of these graphs are not automatically created by some analytical procedure, and must be custom built. However, many of these graphs are commonly used in the Health and Life Sciences industry, and there is an effort in the industry to standardize. This book describes how to create such graphs for intermediate and advanced graph programmers.

# **Prerequisites**

Some knowledge of SAS DATA step programming may be required to get the data into the shape needed for the graphs. Knowledge of SG procedures and GTL will be helpful, but is not required.

# **Scope of This Book**

This book includes detailed instructions about how to create some of the standard, commonly used graphs for analysis of data in the Health and Life Sciences industry. The book provides some introductory information on the use of SG procedures and GTL.

However, this book does not cover the features of SG procedures or of GTL in depth. Such comprehensive information is beyond the scope of this book.

# **About the Examples**

### **Software Used to Develop the Book's Content**

All the graphs shown in this book are generated using SAS 9.4 or SAS 9.3.

#### **Example Code and Data**

To access the book's example code and data, visit the author's page at <a href="http://support.sas.com/publishing/authors">http://support.sas.com/publishing/authors</a>. Select the name of the author. Then, look for the book cover and select Example Code and Data.

If you are unable to access the code through the website, send email to saspress@sas.com.

# **SAS University Edition**

If you are using SAS University Edition to access data and run your programs, ensure that the software contains the product or products that you need to run the code: <a href="http://support.sas.com/software/products/university-edition/index.html">http://support.sas.com/software/products/university-edition/index.html</a>.

# **Output and Graphics Used in This Book**

All the graphs included in the book are created using the program code shown in the chapters. Some appearance options in the code might have been trimmed to fit the space available on the page. The full programs including the data generation and procedure code are available.

# **Additional Help**

Although this book illustrates many analyses regularly performed in businesses across industries, questions specific to your aims and issues may arise. To fully support you, SAS Institute and SAS Press offer you the following help resources:

- For questions about topics covered in this book, contact the author through SAS Press:
  - Send questions by email to <u>saspress@sas.com</u>; include the book title in your correspondence.
  - Submit feedback on the author's page at http://support.sas.com/author feedback.
- For questions about topics in or beyond the scope of this book, post queries to the relevant SAS Support Communities at <a href="https://communities.sas.com/welcome">https://communities.sas.com/welcome</a>.
- SAS Institute maintains a comprehensive website with up-to-date information. One page that is particularly useful to both the novice and the seasoned SAS user is the Knowledge Base. Search for relevant notes in the "Samples and SAS Notes" section of the Knowledge Base at <a href="http://support.sas.com/resources">http://support.sas.com/resources</a>.
- Registered SAS users or their organizations can access SAS Customer Support at
   <a href="http://support.sas.com">http://support.sas.com</a>. Here you can pose specific questions to SAS Customer Support; under
   Support, click Submit a Problem. You will need to provide an email address to which replies

can be sent, identify your organization, and provide a customer site number or license information. This information can be found in your SAS logs.

# **Keep in Touch**

We look forward to hearing from you. We invite questions, comments, and concerns. If you want to contact us about a specific book, please include the book title in your correspondence.

# **Contact the Author through SAS Press**

- Visit the author's page at <a href="http://support.sas.com/author\_feedback">http://support.sas.com/author\_feedback</a>.
- Send comments by email to saspress@sas.com

#### **Purchase SAS Books**

- Visit <u>sas.com/store/books</u>.
- Phone 1-800-727-0025
- Email: sasbook@sas.com

# Subscribe to the SAS Learning Report

Receive up-to-date information about SAS training, certification, and publications via email by subscribing to the SAS Learning Report monthly eNewsletter. Read the archives and subscribe today at http://support.sas.com/community/newsletters/training!

#### **Publish with SAS**


SAS is recruiting authors! Are you interested in writing a book? Visit <a href="http://support.sas.com/saspress">http://support.sas.com/saspress</a> for more information.

# **About The Author**



Sanjay Matange is an R & D Director in the Data Visualization Division at SAS, responsible for the development and support of ODS Graphics. This includes the Graph Template Language (GTL), Statistical Graphics (SG) procedures, ODS Graphics Designer, and other related graphics applications. Sanjay has extensive experience in building complex graphs for all domains including Health and Life Sciences. Sanjay has been with SAS for over 25 years and is coauthor of two patents and the author of three SAS Press books.

Learn more about this author by visiting his author page at <a href="http://support.sas.com/matange">http://support.sas.com/matange</a>. There you can download free book excerpts, access example code and data, read the latest reviews, get updates, and more.



# Gain Greater Insight into Your SAS® Software with SAS Books.

Discover all that you need on your journey to knowledge and empowerment.



